01—Abstract
Summary
Summary of the 8-K filed April 25, 2025. Cited figures are marked; the original filing is the authoritative source.
Colgate-Palmolive reported first quarter 2025 results on April 25, 2025, with a mixed picture: GAAP net sales fell 3.1% to $4.91 billiona, but organic sales rose 1.4%, meaning the decline was driven almost entirely by a 4.4% foreign exchange headwind.
Volume was roughly flat (-0.1%) and pricing added 1.5%. Profitability held up better than sales. GAAP diluted EPS rose 2% to $0.85b, and Base Business (non-GAAP) EPS rose 6% to $0.91, helped by a gross margin expansion of 80 basis points to 60.8% and a 120 basis point increase in GAAP operating margin to 21.9%.
Operating profit grew 3% on a GAAP basis. Net cash from operations was $600 millionc, and free cash flow before dividends was $476 million, down from $555 million a year earlier. Segment performance was uneven.
Hill's (Pet Nutrition) was the standout, with operating profit up 30%d and margin up 510 basis points, and Europe showed strong organic growth of 5.4% and operating profit up 12%. Latin America was the weak spot, with net sales down 8.7% (including a 12.7% FX drag) and operating profit down 14%. North America and Africa/Eurasia also saw profit declines.
Management highlighted leadership in toothpaste (40.9% global share) and manual toothbrushes (31.9%). The company revised its full-year 2025 guidance. Net sales are now expected to be up low single digits, with a low-single-digit FX headwind, and organic sales growth is now 2% to 4%.
Management cited tariffs and volatile global markets as ongoing risks. GAAP and Base Business EPS are both expected to grow low single digits. Note that this 8-K furnishes the earnings release under Item 2.02 and is not deemed filed under the Exchange Act.
02—Key points
Key Highlights
- GAAP net sales declined 3.1% to $4,911 million, but organic sales grew 1.4%; FX was a 4.4% headwind, so the reported decline is mostly currency-driven.
- Base Business diluted EPS rose 6% to $0.91 (GAAP $0.85, +2%), with the Base Business figure excluding a $15 million ERISA litigation charge in SG&A and related items.
- Gross profit margin expanded 80 basis points to 60.8%, and GAAP operating margin rose 120 basis points to 21.9%.
- Hill's Pet Nutrition operating profit jumped 30% to $258 million with a 510 basis point margin gain, while Latin America operating profit fell 14% amid a 12.7% FX drag.
- Full-year 2025 guidance was revised: organic sales growth now 2% to 4%, and EPS growth is low single digits on both GAAP and Base Business bases, with tariffs cited as a key uncertainty.
- Free cash flow before dividends was $476 million, down from $555 million, as operating cash flow fell to $600 million from $681 million on higher receivables and inventory build.
- Advertising investment was $668 million, with management stating advertising rose 30 basis points as a percentage of sales to 13.6%, while dividends paid were $406 million and buybacks were $284 million.
03—Questions
Frequently Asked Questions
Why did reported sales decline if organic growth was positive?
Foreign exchange was a 4.4 percentage point headwind to net sales, which more than offset 1.4% organic growth. The impact was concentrated in Latin America (-12.7% FX) and was partly offset by pricing gains of 1.5%, with volume roughly flat at -0.1%.
Is the earnings improvement sustainable given the margin gains?
Margin expansion came from gross margin improvement and operating leverage, which funded higher advertising. Management said it is maintaining its strategy, but the company also cut its full-year organic growth outlook range and flagged tariffs, so investors should watch whether pricing and cost savings can keep offsetting volume softness and currency pressure.
Which segments are driving performance and which are lagging?
Hill's (up 30% in operating profit) and Europe (up 12%, with 5.4% organic growth) led. Latin America (-14%), North America (-8%), and Africa/Eurasia (-14%) lagged. North America's net sales fell 3.6% and organic sales fell 3.0%, with volume down 2.3%.
How did the ERISA litigation and productivity items affect reported results?
The company recorded a $15 million ERISA-related charge in SG&A and a $50 million non-service postretirement benefit item. Excluding these items and tax effects, Base Business EPS was $0.91 versus GAAP EPS of $0.85. The prior-year quarter included 2022 Global Productivity Initiative charges, which were excluded from the prior-year Base Business figures.
Is this 8-K a material new disclosure, and how should investors weigh the guidance change?
The 8-K furnishes the quarterly earnings press release under Item 2.02 and is not deemed filed for Section 18 purposes. The main new information is the revised FY2025 guidance, which reflects tariffs in effect as of April 24, 2025 and current spot FX rates. Because the guidance is based on those assumptions, future tariff or currency changes could move results materially.
04—Continue